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In 1954 Dustan ci at. (1) reported that some
patients receiving hydralazine for the treatment
of hypertension developed clinical and labora-
tory findings characteristic of lupus erythema-
tosus. Since that time many investigators have
attempted to produce a lupus erythematosus-
like illness by feeding animals hydralazine. Un-
fortunately, such studies have been the subject of
much dispute.
Comens (2) was the first to report positive
results. He produced in dogs a syndrome char-
acterized by L.E.-like cells, thickening of the
basement membranes of renal glomeruli, anemia,
leukopenia and aberrations in serum proteins. His
evidence also suggested that manganese defi-
ciency might play an important role in the genesis
of the hydralazine syndrome (3). Dubois (4) and
Earl (5) were unable to confirm these findings
while Gardner (6) found L.E.-like cells and noted
glomerular basement membrane thickening but
felt that the latter was within normal limits for
the dog. Zingale ci at. (7) reported false positive
Wassermann reactions in two dogs as well as
elevated beta globulins in similar experiments.
They did not find L.E.-like cells or histopathologi-
cal changes compatible with lupus erythematosus.
Pigs (8) and rats (9) also have been used in
hydralazine feeding experiments, but no lupus
erythematosus-like syndrome has been pro-
duced. Siguier ci at. (10) used the guinea-pig in
an effort to reproduce this lupus-like syndrome.
Their positive data included classical L.E. cells
in four out of 15 animals and LB-like cells in
three others, leukopenia and anemia, elevated
alpha-2-globulins without hypergammaglobu-
linemia, and anorexia, apathy and weight loss
leading to death within two to four months.
Histological examination of the organs was not
performed.
We decided to reinvestigate this problem be-
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cause of the urgent need for an experimental
model for lupus erythematosus. Any clue to the
mechanism by which hydralazine produced a
syndrome, clinically and pathologically almost
identical to lupus erythematosus, would be of
obvious value. The guinea-pig was selected for
our investigation not only because of Siguier's
recent work but also because of the experiments
by Carrera ci at. (11) which showed that guinea-
pig leukocytes were very sensitive to the action
of human L.E. serum.
We also wanted to test a new hypothesis,
namely, the role of riboflavin deficiency in the
genesis of the hydralazine syndrome and lupus
erythematosus. The anti-malarials atabrine
and chloroquine are very effective in treating
lupus erythematosus. The chemical configura-
tions of riboflavin, atabrine, and ehloroquine are
quite similar to one another (Fig. 1). If weanling
rats are made riboflavin deficient (12) and are
fed atabrine, they will grow normally. Atabrine
substitutes for riboflavin in the flavin containing
enzymes because of its structural similarity. In
euro, however, atabrine inhibits flavin containing
enzymes (13, 14) by irreversibly combining with
the protein moiety of the enzyme—again because
of its structural similarity.
Hydralazine is somewhat similar in structure
to the above-mentioned compounds (Fig. 1).
It was thought that if hydralazine, which pro-
duces a lupus erythematosus-like illness in hu-
mans, were fed to riboflavin-deficient guinea-pigs,
it might be easier to produce the lupus-like dis-
order.
A third experiment was suggested by the ob-
servation that mesantoin and related (anti-
convulsant medications can cause a lupus-like
illness (15, 16). Mesantoin (Fig. 1) was given to
normally fed and riboflavin deficient guinea pigs
in an effort to enhance the production of this
syndrome.
METHODS
Four experimental designs were used:
Experiment A. All animals were fed guinea-pig
chow, supplemented twice weekly with raw
cabbage. Nineteen animals were given hydrala-
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FIG. 1. Note the similarity in the chemical structures of atabrine, chioroquine, and riboflavin. Hydra!-
azine bears less resemblance to these compounds. The hydantoin ring of mesantoin is similar to one of
the rings of the riboflavin molecule.
zine,t 19 were given mesantointt dissolved in pro-
pylene glycol, and 23 were housed under the same
conditions to serve as controls. Five of the third
group received propylene glycol as a specific con-
trol for the mesantoin treated group.
Experiment B. All animals were placed on a
riboflavin-deficient diet. Seventeen animals were
given hydralazine and eight served as controls.
Another 17 animals received mesantoin in propyl-
ene glycol while eight control animals were given
propylene glycol.
Experiment C. All animals were fed guinea-pig
chow supplemented twice weekly with raw
cabbage. Seventeen received hydralazine as in the
above experiments and eight served as controls.
In addition all 25 animals were irradiated with
ultraviolet light from a Westinghouse FS40T12
fluorescent sun lamp. The lamp, housed in an
Alzac aluminum reflector, was placed 12 inches
above the animal's back. The exposure began at
five minutes a day and was gradually increased
to a maximum of two hours daily, six days a week.
The guinea-pig's hair was removed first by shaving
and then by a chemical depilatory, Nair®, prior
to irradiation.
Experiment D. All guinea-pigs were placed on a
riboflavin deficient diet and exposed to ultraviolet
irradiation as outlined above. Seventeen guinea-
pigs were fed hydralazine and eight served as con-
trols. All guinea-pigs used in this last experiment
were female whereas previously there was an equal
distribution of males and females. In addition,
genetically heterogenous guinea-pigs purchased
from local farms were used in the first three experi-
ments. These animals had a high incidence of
chronic pneumonitis. Consequently, in the fourth
experiment, albino guinea-pigs of the inbred
Hartley strain were used because they are very
resistant to the development of pneumonitis. All
animals weighed between 300—350 g. at the start of
the experiments.
Hydralazine hydrochloride was dissolved in
distilled water and given orally by syringe once
daily seven times a week. Mesantoin was dissolved
in propylene glycol and administered the same
way. In Experiment A, the hydralazine dose was
10 mg/Kg for the first three months. The results
described by Siguier et cii. were not obtained, so
the dose was increased slowly to 300 mg/Kg during
the subsequent six months. The mesantoin dose
was 10mg/Kg throughout both Experiments A and
B.
In Experiments B, C, and D, the hydralazine
dose was 100 mg/Kg.
All animals were bled before the experiments
were begun and their sera frozen and stored at
—20° C. Blood was obtained at weekly to monthly
NHz
NH
HYDRA LAZ INE
t Generous supplies of hydralazine were fur-
nished by Dr. E. Jack of the Ciba Pharmaceuti-
cal Products, Inc.
if Mesantoin was furnished by Dr. H. Bircher
of the Bandoz Pharmaceutical Company.
EXPERIMENTAL LIJPUS ERYTHEMATOSTJS 319
intervals for L.E.-cell tests, white blood counts,
hematocrit, blood urea nitrogen, and serum pro-
tein eleetrophoresis. Urinalyses were done every
two weeks, and the organs were examined histo-
logically when the animals died.
L.E.-eell tests were performed by the methods
of Snapper and Nathan (17), Zinkham and Conley
(18), and Laehmann (19). In Snapper and Nathan's
method, guinea-pig leukocytes served as sub-
strates in the rings. In Lachmann's method,
guinea-pig leukocytic nuclei served as substrates,
and guinea-pig white cells served as the phagocytic
component.
We also performed induction tests using these
identical procedures with potent lupus serum act-
ing on guinea-pig leukocytes. Carrera's method
(11) was also employed for this purpose. In some
of the induction tests human leukocytes served as
the phagocytic element. The purpose of these pro-
cedures was to determine what morphologic
changes are actually induced in guinea-pig leuko-
cytes by the action of lupus serum, and the ease
with which they are produced.
In order to detect anti-nuclear factors in the
sera of the treated guinea-pigs, Coon's immuno-
fluorescent technic was employed. The method
of Calabresi (20) was modified for this purpose: a
smear was made with normal guinea-pig blood and
fixed in absolute methanol for 15 minutes. A few
drops of the test animal's undiluted serum were
placed on the feather edge of the smear which was
incubated in a moist petri dish at 37° C. for 30
minutes. Then the slide was washed under running
tap water for 20 minutes, followed by air drying.
Fluorescein conjugated rabbit anti-guinea-pig
gammaglobulin was placed on the same area. The
slide was kept in a moist petri dish for 30 minutes
at room temperature and then washed under
running water again. The preparation was viewed
with a Leitz fluorescence microscope employing a
IIBO 200 Osram lamp.
One looks for nuclear fluorescence without cyto-
plasmic fluorescence. If more than 50% of the
nuclei fluoresce with a typical yellow-green color,
the test is considered positive. As a control, smears
were incubated with fluorescein conjugated anti-
serum alone as well as with non-fluorescein con-
jugated rabbit anti-guinea-pig gammaglobulin
prior to incubation with tbe fluorescein conjugated
antiserum. In the first instance there was no non-
specific nuclear fluorescence. In the second, the
nonfluorescein conjugated anti-serum blocked
production of nuclear fluorescence.*
Friou's nucleohistone "lupus globulin" test
also was employed (21), as was Calabresi's original
technic using human blood smears in an effort to
detect anti-nuclear factors in the guinea-pigs'
sera.
Serum protein electrophoresis was performed
* The fluorescein conjugated and non-conju-
gated antisera were obtained from Microbiological
Associates, Bethesda, Maryland.
in a Spinco-Durrum cell at pH 8.6 in Veronal
buffer.
Post-mortem examination of the organs was
performed. Alternate kidney sections were stained
with hematoxylin and eosin and periodic acid
Schiff technic.
The riboflavin deficient diet was modified
slightly from that of Reid (22). The composition
of the diet is given in Table 1. The animals adapted
themselves to the diet quite readily if it was in-
troduced gradually. Riboflavin levels were de-
termined in the diet, feces, and urine of two ani-
mals by Dr. Lester Hankin of the Connecticut
Agricultural Station using the L. casei microbio-
logical method. The urine was collected in brown
bottles covered with foil and kept acid with 10 ml
of 6 N hydrochloric acid. The riboflavin content
of the diet was found to be 0.08 y/gram. The ani-
mals ate 30—40 grams of diet per day. The urinary
excretion of riboflavin was 0.007 y/ml with a total
of 25 ml excreted per day by one animal and 100 ml
by the second. The focal content of riboflavin in
the first animal was 15.3 y/gm feces per day (total
feces 1.98 gm/day) and 5.91 y/gm feces per day in
the second animal (total 2.63 gm/day). The clini-
cal appearance of the riboflavin deficient animals
was one of apathy, roughening of the hair coat,
and loss of weight over a two-week period leading
to death. There was no dermatitis. If 200 y/day of
riboflavin was given orally to the guinea-pigs after
they began to lose weight, they responded immedi-
ately with a sustained weight gain. They became
active and regained their appearance of well-
being. Figure 2 shows a typical response. Using
these clinical signs, weight curves, and response to
riboflavin administration as criteria, it appeared
that 60% of the treated animals in Experiments B
and D became riboflavin deficient.
RESULTS
Negative results can be summarized as follows:
(1) The mesantoin treated animals showed no
abnormalities.
(2) The riboflavin deficient diet, ultraviolet
irradiation, and use of female animals did not
seem to enhance the production of hydralazine
disease.
(3) There were no significant abnormalities in
the white count, hematocrit, urinalysis, blood
urea nitrogen, or serum protein electrophoresis.
(4) Chronic wasting disease secondary to
hydralazine, described by Siguier et at., was not
seen.
The following positive results were obtained:
(1) Seventeen per cent of the animals receiving
hydralazine had L.E.-like cells and/or showed
the presence of anti-nuclear activity when their
blood or serum was appropriately tested.
(2) In 17% of the animals minimal thickening
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TABLE 1
Composition of riboflavin deficient diet
Ingredients Amount Ingredients Amount
gm/Kg diet gm/Kg diet
Casein (Vitamin-free)' 280 Sodium Chloride 2.8
Sucrose 170 Sodium Phosphate, Dibasic, Anhydrous 7.3
Corn Starch 200 Potassium Iodide 0.036
Cellulose (Aiphacel)' 150 Manganous Sulfate 0.3
Potassium Acetate 25 Choline Chloride1 2
Magnesium Oxide 5 Ascorbic Acid1 2
Salt Mixture (11MW.)1 50 Cod Liver Oil, U.S.P.' 2
Corn Oil (Mazola) 73 Vitamin Mixture 10
grams grams
Nicotinic Acid 40 Folic Acid 1.2
Calcium Pantothenate 3 Inositol 400
Pyridoxine Hydrochloride 3.2 Vitamin K 0.4
p-Aminobenzoic Acid 4 Vitamin B,2, Crystalline 0.01
Thiamine Hydrochloride 3.2 DL-Alphatocopherol Powder (250 i.u. Vit.
E/gram)
60
Biotin 0.120 Sucrose 1484.9
1 These components plus the individual vitamins were obtained from Nutritional Biochemical Cor-
poration, Cleveland, Ohio.
of the renal glomerular basement membrane
occurred, but no other organs showed histological
changes compatible with lupus erythematosus.
(3) The most striking positive findings were in
animals receiviog hydralaziue for at least six
months.
In Table 2 the results of the four experiments are
summarized.
In Experiment A, an epizootic characterized by
clinical and pathological evidence of pneumonitis
killed 15% of all the animals in the first six weeks.
Thereafter, only a rare animal death could be
attributed to pneumonitis. Before Experiment A
was begun, serum protein electrophoresis was per-
formed on all the animals. Many of them showed
an alpha-2 globulin peak as high as Siguier et at.
had found after their animals had received hy-
dralazine. The gammaglobulin fraction rose in
our animals as they contracted pneumonitis
and subsequently died. At the conclusion of
Experiment A, almost every animal had histologi-
cal evidence of a chronic granulomatous pneu-
monitis even though some appeared clinically
healthy during the course of the experiment.
Because of these findings any changes in the
serum protein electrophoresis were disregarded.
Therefore, Hartley strain guinea-pigs, which are
resistant to this type of infection, were used in
the last experiment. There were no changes in
serum protein electrophoresis and no evidence of
pneumonitis when the experiment was terminated
after three months.
The clinical course of the guinea-pigs in these
experiments was different from that reported by
Siguier et at. (10). Our animals did not exhibit a
chronic wasting disease. Most of them grew nor-
mally and appeared well until three or four days
before they died. During the terminal episode
they developed acute weight loss, apathy, and
seizures. A few animals who were on very high
doses of hydralazine, 150—300 mg/Kg per day,
maintained a uniform weight before expiring in
an identical fashion.
Experiment A lasted for nine months and gave
the greatest number of positive findings. Experi-
ments B, C and D lasted for only three months.
The reason for this difference is that riboflavin
deficient guinea-pigs do not survive very long if
riboflavin is not made available to them. It was
hoped that if riboflavin deficiency were an im-
portant factor in the genesis of this syndrome, the
period of survival would have been sufficient to
allow its production.
The L.E. cell tests were characterized by the
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presence of hematoxylin-like bodies, nuclear
swelling, rosette formation and L.E.-like cells.
Figures 5—11 illustrate these changes. Almost
identical morphological changes could be found
when human lupus serum was incubated with
guinea-pig leukocytes by the variety of methods
listed previously. In the induction tests with hu-
man lupus serum and guinea-pig white cells (Figs.
3, 4) the L.E. inclusion bodies were not always
formed as single completely homogeneous units.
Many times the inclusion bodies were either frag-
mented, made up of many small homogeneous
blobs, or seemingly composed of stringy material.
When human L.E. cell preparations were scruti-
nized carefully, similar changes could be found in
addition to the more prevalent classic L.E. cell.
The L.E.-like cell phenomena listed above were
found only in treated animals, and never in the
L.E. cell tests done on control animals. The L.E.
cell phenomena when present, however, were not
plentiful and a diligent search was necessary to
find them. The changes most frequently found
were those of hematoxylin-like bodies and nuclear
swelling. The changes illustrated in Figures 3—11
are proposed as representing the L.E. cell phe-
nomena in the guinea-pig.
When the sera of these animals were tested
for anti-nuclear activity, there was specific nu-
clear flourescence only when guinea-pig leuko-
cytes were used as the substrate. The nuclear
fluorescence could be blocked by incubating the
blood smears with non-fluorescein conjugated
antiserum prior to incubation with the fluorescein
conjugated material. However, these sera did
not give nuclear fluorescence when tested against
calf thymus nueleohistone spots as performed by
Friou (21). Nor did they show nuclear fluores-
cence with human leukoeytes as the substrate.
These guinea-pig sera lost activity after being
frozen and thawed three to four times.
In order to sec if a species difference might
account for the failure of guinea-pig antinuclear
factor to react with human and calf nuclear ma-
terial, the following reverse experiment was per-
formed. Human lupus serum was incubated on
smears from rabbit, dog, hamster, and guinea-
pig blood. Specific nuclear fluorescence was seen
in all cases except when guinea-pig blood was used.
In order for human lupus serum to exert anti-
nuclear activity against guinea-pig white cell
nuclei, it was necessary to isolate guinea-pig white
blood cells by the dextran method (23), freeze and
thaw them and then make a smear of the disrupted
cells. After this process, specific nuclear fluores-
cence was seen. There was no evidence of in-
hibiting substances in guinea-pig blood that could
account for the failure of human L.E. serum to act
on guinea-pig blood smears.
This resistenee of guinea-pig white cells to the
action of human lupus serum correlated well with
the difficulty encountered in producing L.E. cells
in the induction tests. L.E. cells could be formed
by incubating lupus serum with guinea-pig white
cells, but it was not accomplished as easily as
previous authors had reported (11). In fact, L.E.
cell phenomena could be produced easily and con-
sistently only when lupus serum was incubated
with dextran isolated guinea-pig leukocytic nu-
clei which had been disrupted by freezing and
subsequently exposed to viable human leuko-
cytes. When these first two components were pre-
sented to viable guinea-pig leukocytes very few
phagoeytized L.E. bodies were seen. However,
many swollen and homogeneous appearing nu-
clei and hematoxylin-like bodies were seen to be
lying free in the smear. This indicated that, al-
though the first stage of the L.E. cell phenomena
could be easily produced, the viable guinea-pig
leukoeytes were unable to complete the second
or phagoeytie stage. This correlates well with
the predominant type of L.E. cell-like phenom-
enon seen in the preparations from the experi-
mental animals (Figs. 4, 6, 7). These morphologic
changes are quite analogous to the findings of
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(TITLE Fio: 2): Effect of riboflavin-deficient
diet on the weight of guinea pigs and the response
to subsequent administration of riboflavin.
FIG. 2. This graph showing the response of an
individual guinea-pig is representative of the
responses of the other animals. After an initial
weight loss during adaption to the diet, the ani-
mals maintained a steady weight for 4-6 weeks. At
this point, they began to lose weight over a 10—14
day period. If riboflavin was not supplied at this
time, the animals would die. When riboflavin was
given orally while the animals were still on the
diet, a prompt and sustained weight gain occurred.
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TABLE 2
Effects of hydralazine on guinea-pigs
Animal No. Survival Time(months)
Died (D) or
Sacrificed (5) Time of Appearance of LE Cell Phenomena
Time of Appear-
auce of Serum
Antinuclear Activity
Renal Lesions
at Autopsy
Experiment A'
1
2
3
4
5
6
7
9
9
7
1.75
4
3
6
D
D
D
D
D
D
D
Rosette formation—7 months
none
none
Nuclear swelling—i month
ilematoxylin bodies—4 months
none
none
4 + at 9 mo.
4+at7mo.
4+at6mo.
1 + at 0.5 mo.
1 + at 4 mo.
1+at3mo.
none
0
+
0
0
0
0
+
Experiment B2
1
2
3
4
5
6
7
3
3
1.5
3
3
2
2
S
S
D
S
S
D
D
none
none
Hematoxylin bodies—1.5 mo.
Nuclear swelling—3 mo.
none
none
none
1+at3mo.
4+at3mo.
none
none
none
none
none
+
0
+
0
+
+
+
Experiment C3
1
2
2
3
D none none
S none none
+
+
Experiment D4
1
2
3
4
3
3
3
3
S Nuclear swelling—2 mo. none
S LE eell—2 mo. none
S none none
S none none
+
+
+
+
'Experiment A—normal diet, hydralazine treated. 19 animals total.
in the first 4—6 weeks and are not included in this total.
4 animals died of pneumonia
2 Experiment B—riboflavin deficient diet, hydralazine treated. 17 animals total.
Experiment C—normal diet, hydralazine treated, UV irradiation. 17 animals total.
Experiment D—riboflavin deficient diet, hydralazine treated, UV irradiation, female guinea pigs.
18 animals total.
Robineaux (24) and Rifkind and Godman (25)
who were able to follow the development of the
L.E. cell phenomenon. They noted that the im-
mediate action of lupus serum on white cells was
swelling and homogenization of lymphocytie or
polymorphonuelear leukocytie nuclei. The swollen
body was extruded into the media while the cyto-
plasm was left behind. It was then phagocytized
by a viable leukocyte to become the classic L.E.
cell.
These findings in the induction tests may in
part explain why the guinea-pig sera reacted with
homologous white cells and not with human white
cells. It is possible that, just as the guinea-pig
white cell is resistant to the action of human lu-
pus serum, so is the human white cell resistant to
the action of guinea-pig anti-nuclear serum. Un-
fortunately, these guinea-pig sera were not tested
against frozen and thawed human white cells.
A four plus anti-nuclear reaction means that
80—100% of white blood cells show nuclear fluo-
rescence. A one plus reaction means that 10%
of white blood cells exhibited the same reaction.
It may be a weakly positive reaction because
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Fin. 3. Cell produced by the action of human lupus serum on guinea-pig leukocytes. Note that the
inclusion body is fragmented and lumpy but still homogeneous. This was the predominant type of L.E.
cell produced in the induction tests. )( 2160.
Fin. 4. Homogenization and swelling of white cell nuclei produced by the action of human lupus serum
on guinea-pig leukocytes. Compare with figures 6 and 7. X 2160.
Fin. 5. Homogeneous basophilic bodies lying free in an L.E. cell test from a hydralazine treated ani-
mal. They are morphologically indistinguishable from hematoxylin bodies seen in human L.E. cell tests.
(Experiment A, animal No. 5). X 2160.
Fin. 6. Homogenization and nuclear swelling present in L.E. cell test. (Experiment B, animal No. 4).
>< 2160.
Fin. 7. Many leukocytes undergoing nuclear swelling and homogenization. (Experiment A, animal
No. 4). x 2160.
FIG. 8. Two polymorphonuclear leukocytes are in close proximity to a basophilic homogeneous body,
as if about to phagocytize it. (Experiment A, animal No. 5). X 2160.
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FIG. 9. This L.E. cell test shows a similar homogeneous basophilic body in the process of being phago-
cytized by a guinea-pig white cell. Note the lack of chromatin structure in these bodies in figures 8 and
9. (Experiment B, animal No. 3). X 2160.
FIG. 10. Rosette formation with L.E.-like cell present. Note that the inclusion material although
homogeneous is lumpy and fragmented, and similar to that seen in figure 3. (Experiment A, animal No.
1). X 2160.
FIG. 11. L.E. -like cell with smaller inclusion body. Note its similarity to the inclusion material in
figure 3. (Experiment D, animal No. 2). X 2160.
FIG. 12. P.A.S. stained section of renal glomerulus from a control guinea pig. Note fine delicate base-
ment membrane and the moderate cellularity present. X 960.
.FIG. 13. P.A.S. stained section of renal glomerulus from another control animal. Arrows indicate
degree of irregular basement memrane thickening. N 960.
FIG. 14. The arrows show the degree of glomerular basement membrane thickening seen in 13 hydrala-
zinc treated guinea-pigs. The basement membrane stained somewhat more deeply and homogeneously
with P.A.S. stain than did the corresponding area of control animals. The basement membrane thicken-
ing was also of slightly greater degree. P.A.S. stain. N 960.
-
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when control smears incubated with normal
guinea-pig serum are examined, only 1—2% of
the white cells show nuclear fluorescence. This
same percentage is seen in preparations from
normal human beings. None of the sera obtained
from these animals before the onset of the experi-
ment showed anti-nuclear activity.
In a few animals, the renal glomeruli showed
slight thickening of the basement membranes
with the P.A.S. stain (Fig. 14). It is difficult to
assign significance to these findings because nor-
mal guinea-pig kidneys show some irregular
thickening of the basement membrane (Figs.
12, 13). The thickening found in the hydralazine
treated animals was only slightly more than that
of the controls. These findings were not correlated
with any changes in the urine or blood urea nitro-
gen. The remainder of the kidneys as well as the
other organs did not show abnormalities com-
patible with lupus erythematosus. Additional
experiments are required to determine whether
or not these changes are analogous to wire
loop lesions seen in renal tissue from patients
with lupus erythematosus.
DIscussIoN
These studies support the most significant
claims of previous investigators in this area:
hydralazine does produce an illness in experi-
mental animals and this illness closely resembles
lupus erythematosus. However, the criteria for
the evaluation of L.E. cell phenomena in the
experimental animal must be revised. Inclusion
bodies may be fragmented and not as completely
homogeneous as usually described for the classi-
cal L.E. cell. L.E. cell induction tests performed
with human lupus serum and guinea-pig leuko-
cytes make this clear. In addition, only the first
stage of the L.E. cell phenomenon may be pres-
ent. A phagocytic defect in the animal's own
white cells may prevent the second stage from
occurring to any significant degree.
Two other investigations are relevant: Mies-
cher (26) was able to produce a few L.E.-like
cells in a guinea-pig that was immunized with
liver cell nuclei. Finch et at. (27) produced L.E.-
like cells by incubating human leukocytes with a
rabbit anti-human leukoeyte serum. The inclu-
sion bodies in the L.E.-like cells in these experi-
ments very closely resemble those shown in Fig.
10. These experiments in addition to our own
L.E. cell tests and L.E. induction tests constitute
further morphologic evidence for the presence of
an anti-leukocytic factor in the sera of hydrala-
zine treated guinea-pigs.
In previous investigations, it was necessary to
incubate the animal's serum with human white
cells to produce L.E.-like cells. In our work, L.E.-
like cells were produced by the action of guinea-
pig serum on guinea-pig leukocytes. On a few
occasions guinea-pig sera were incubated with
human leukocytes, but no L.E.-eells were ob-
served.
Anti-nuclear factors have been demonstrated
for the first time in hydralazine disease in a lab-
oratory animal. Unfortunately, these factors were
labile when frozen and thawed several times.
Friou (28) tested sera from two patients with
hydralazine disease and found that titers of anti-
nuclear activity were low when compared with
those of patients having lupus erythematosus.
Although the presence of anti-nuclear activity
in the animal's serum did not always correlate
with the demonstration of L.E. cell phenomena,
this finding was not unexpected. A recent review
by Larson (29) contains data which show that
approximately one-sixth of patients with lupus
erythematosus have positive L.E. cell tests with-
out demonstrable anti-nuclear factors. The other
combinations of anti-nuclear activity alone or in
conjunction with L.E. cell phenomena also are
well known in human clinical material. The re-
sults in our animals are similar.
Although the riboflavin hypothesis was not
supported, it may be worth pursuing further.
Only 60% of the adult guinea-pigs were made
riboflavin deficient. If they could be kept in a
borderline deficient state for longer periods of
time, perhaps hydralazine disease could be pro-
duced more easily. Synthetic riboflavin antago-
nists in conjunction with the diet might produce
a much higher percentage of riboflavin deficient
animals and help to enhance the production of
this lupus-like syndrome.
The renal glomerular changes are difficult to
interpret. Normal guinea-pig kidney has base-
ment membrane changes that are slightly ab-
normal by human standards (Fig. 13). It is on
this base that further abnormalities are super-
imposed. The irregular basement membrane
thickening seen in hydralazine treated animals
is only slightly greater than that of the control
animals. Further experiments may clarify this
problem. A similar difficulty may play a role in
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the controversy over the renal lesions in the hy-
dralazine treated dogs. From what we know of
the clinical course of hydralazine patients, and
from autopsy findings in one case (30), there is
no reason to think that "wire loop" lesions should
be produced by hydralazine in an experimental
animal. Patients who developed the syndrome
showed a decrease in albuminuria and an im-
provement in urinary sediment. The one autop-
sied case did not show glomerular basement mem-
brane thickening. Another case of "hydralazine
poisoning" which was examined at autopsy
showed wire loop lesions in the kidneys (31). How-
ever, it was a very atypical case and it might
not represent hydralazine toxicity.
It has not been possible to duplicate many of
the findings of Siguier et al. One major differ-
ence exists between their protocol and ours. They
put hydralazine in the drinking water so that
the animals had constant exposure to the drug
whereas we administered it once daily by mouth.
This difference could account for our failure to
confirm all their findings.
Since only 17% of our animals developed lab-
oratory changes similar to those found in lupus
erythematosus, we do not yet have a practicable
experimental model. It is possible that the guinea-
pig is a poor animal to study since its leukocytes
are relatively resistant to the action of human
L.E. serum as a substrate for either fluorescent
antiglobulin or L.E. cell induction tests.
SUMMARY
1. Hydralazine was administered to a large
group of guinea-pigs. L.E.-like cells and serum
anti-nuclear factors developed in 17% of 70 ani-
mals. The most striking abnormalities occurred
in animals that received hydralazine for at least
six months.
2. Riboflavin deficiency, ultraviolet irradiation,
and the use of female guinea-pigs did not enhance
the production of a lupus erythematosus-like
syndrome with hydralazine.
3. Minimal thickening of the glomerular base-
ment membranes occurred in some animals. This
finding was difficult to interpret since there were
no associated abnormalities in the urine or blood
urea nitrogen.
4. No changes in the hemogram or serum pro-
teins occurred. There was no distinctive clinical
illness associated with the abnormal laboratory
findings.
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